Evaluating a Treatment for HER2-Positive Metastatic Breast Cancer

Host: Pavani Chalasani, MD, MPH Guest: Erika Hamilton, MD A new treatment option for breast cancer may alter the treatment landscape for patients with HER2-positive metastatic breast cancer. Joining Dr. Pavani Chalasani to share data from the DESTINY Breast03 trial is Dr. Erika Hamilton, the Director of the Breast Cancer and Gynecologic Cancer Research Program at Sarah Cannon Research Institute at Tennessee Oncology.